We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App





COVID-19 Severity Test Reads Immune System in Real Time Using Machine Learning for Predicting Severe Outcomes

By LabMedica International staff writers
Posted on 28 Jul 2021
A new COVID-19 test reads the immune-system in real time to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome.

MeMed (Haifa, Israel) has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity - a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 disease is likely to experience severe outcomes. More...
The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key, and aims to help physicians identify who may benefit from escalated care and who may be safely discharged from the hospital and instructed to self-isolate at home.

MeMed COVID-19 Severity is a predictive and actionable patient management tool. The test enables physicians to detect early the likelihood of deterioration in patients affected by COVID-19 and provides a leap forward in COVID-19 patient management. MeMed has recently published the results from a multinational derivation study, demonstrating the signature’s ability to accurately predict severe COVID-19 respiratory failure. The company has completed an additional independent multinational validation study; the results will be revealed in coming months.

“I am delighted that we are now able to commercialize a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation,” said Eran Eden, MeMed’s co-founder and CEO. “MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics. It is another exciting step in the company’s long-term vision of harnessing the power of the host-immune response in order to transform the way infections are detected and managed.”

“Highly sensitive and accurate diagnostic and prognostic tests are key tools for clinicians,” said Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center. “As an ER doctor myself, I am fascinated by the potential for host immune response technologies to help predict patient outcomes. Tools like MeMed COVID-19 Severity are a win-win solution: doctors can assess the likelihood of patients suffering from severe complications, enabling tailored treatments or discharge if the risk of deteriorating is low.”

Related Links:
MeMed


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.